OSI Pharmaceuticals, Genentech announce results of Tarceva trial
MELVILLE, N.Y. A drug used to treat non-small cell lung cancer and pancreatic cancers extended the survival of patients with advanced NSCLC taking it immediately after chemotherapy, according to results of a late-stage clinical study.
OSI Pharmaceuticals and Genentech announced the results of a phase 3 trial of Tarceva (erlotinib), which they will present at the 13th World Congress on Lung Cancer, on Aug. 4 in San Francisco.
“This study has now not only confirmed that immediate treatment of Tarceva after initial chemotherapy delayed the progression of disease, but also importantly helped patients in the study live longer,” principal investigator Federico Cappuzzo of the Instituto Clinico Humanitas IRCCS in Milan, Italy, said. “This is good news for doctors and their patients, since advanced lung cancer is one of the most challenging cancers to treat and is often associated with a very short life expectancy.”
Caraco to acquire rights to several drugs from Forest Labs
NEW YORK Generic drug maker Caraco Pharmaceutical Labs will acquire rights to several drugs from Forest Labs under an asset purchase agreement between the two companies.
Caraco announced the agreement Friday as part of a settlement that it and parent company Sun Pharmaceutical Industries had entered with Forest Labs and Danish drug maker H. Lundbeck concerning Caraco’s regulatory approval application for the anxiety and depression drug Lexapro (escitalopram oxalate). Lundbeck had licensed Lexapro to Forest on an exclusive basis in the United States.
Under the agreement, Caraco will take over commercialization and sale of several products from Forest’s Inwood business, paying Forest an advance against royalties. Meanwhile, Forest will reimburse Caraco for a portion of its legal fees and provide licenses to Caraco for certain Lexapro patents as soon as a third-party generic version with Food and Drug Administration approval hits the market.
Watson Pharmaceuticals gets the OK from FDA for new nicotine polacriliex gum
MORRISTOWN, N.J. Watson Pharmaceuticals, a leader in generic and specialty branded pharmaceuticals, announced its subsidiary, Watson Labs, has been granted approval from the Food and Drug Administration to market its nicotine polacrilex gum.
Nicotine polacrilex gum is the generic equivalent of GlaxoSmithKline Consumer Healthcare’s Nicorette Fruit Chill and Cinnamon Surge Coated gums, all of which are available over-the-counter and used to help people stop smoking.
Watson’s nicotine gum will be available as soon as possible in coated fruit and cinnamon flavors.